Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05583942
Other study ID # 22-0488-A
Secondary ID 1R01DK131091-01A
Status Recruiting
Phase N/A
First received
Last updated
Start date September 19, 2022
Est. completion date July 2025

Study information

Verified date January 2024
Source Northwell Health
Contact Christine B Sethna, MD, EdM
Phone 718-470-3491
Email csethna@northwell.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.


Description:

A parallel, double blinded, randomized placebo controlled trial comparing daily taVNS use with sham therapy will be conducted in children 3 to 17 years of age with SRNS. Ten participants with SRNS, defined as lack of response to steroids after 4 weeks, will be randomized 1 to 1 to taVNS or sham therapy. Participants will be enrolled at two pediatric tertiary hospitals over a two year time period, with completion of the study by year three. All participants will perform daily taVNS therapy (active for taVNS arm or inactive for sham arm) for 5 minutes each day for a total of 26 weeks. Participants will monitor heart rate with each treatment and log home urine results. Participants will be monitored monthly with in person study visits at Weeks 8, 16 and 26 alternating with virtual telehealth visits at Weeks 4, 12 and 20. Biosample specimens will be collected at baseline, 8 weeks, 16 weeks and 26 weeks. There will be a follow up period of an additional 26 weeks. All participants will be given the option to receive the active taVNS treatment at the end of the randomized period. Study Phases The study will consist of three parts. Part 1 - Screening Period- up to 8 weeks. Informed consent/assent will be obtained at screening prior to the conduct of any study-related procedures. Participants will be screened to confirm inclusion/exclusion criteria are met. Participants must be off steroid treatment for 14 days prior to Day 1 and the participant must be in remission (negative UPC on first morning urine) on Day 1. Part 2 - Randomized Control Period - 26 weeks: Thirty participants with FRNS who meet all of the eligibility criteria will be randomized 1:1 to either taVNS or sham treatment. A trainer will instruct the parent/guardian on use of the device at the randomization visit. Participants will use the intervention device as directed for 5 minutes per day for 26 weeks. Participants will be monitored monthly with in-person study visits at Weeks 8, 16 and 26 alternating with virtual remote video visits at Weeks 4, 12 and 20. The visit window will be +/- 7 days. At each in person visit, we will conduct: - Vital signs and physical examination - Assessment for nephrotic syndrome relapses. Home urine protein logs will be reviewed. - Blood and urine samples will be collected at each in person visit. - Assessment of study intervention adherence. Parents/guardians will meet with the trainer and will be reoriented on taVNS device use at each visit as a safety measure. The device counter number will be recorded as a measure of adherence. - Monitor for adverse events and tolerability: Parents/guardians will share a study log with investigators, which describes daily taVNS use, side effects, and any changes in heart rate. At each virtual remote video visit, we will observe the participant while doing the intervention procedure, assess for nephrotic syndrome relapses, and monitor for any adverse events. Part 3 - Follow Up Period - 26 weeks: At the completion of the randomized period, participants will be followed for an additional 26 weeks to assess clinical status. For those who stop the intervention, study visits will occur in-person during regularly scheduled clinical visits or via telehealth visit every 8 weeks, whichever is sooner. Participants will be assessed for the number of nephrotic syndrome relapses and home urine protein logs will be reviewed. First morning UPC will be recorded. All participants will be given the option to receive the active taVNS treatment at the end of the randomized period. Unblinding of treatment assignment from the randomized phase will not occur prior to consent for open-label use. As open-label extension trials may introduce significant bias, data obtained from these participants will not be considered part of this research and no statistical analysis will be carried out. However, clinical status and safety will continue to be monitored. In person study visits will occur every 8 weeks for those continuing use of taVNS.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 17 Years
Eligibility Inclusion Criteria: - Steroid Resistant Nephrotic Syndrome- defined as lack of remission after 4 weeks of therapy of prednisolone/prednisone at standard dose1 - Age 3-17 years - eGFR =30 ml/min/1.73 m2 (by modified Schwartz formula) - MCD or FSGS diagnosis (per biopsy) - Urine protein:creatinine (UPC) greater than 1.0 - Stable immunosuppression and ACE inhibitor/angiotensin receptor blocker treatment regimen for at least three months - Evidence of B cell repletion for those exposed to rituximab - Informed consent from the parent or guardian and assent from a minor of = 7 years - Ability to comply with the study protocol, in the investigator's judgment Exclusion Criteria: - Secondary causes of nephrotic syndrome (e.g. genetic, congenital, infectious) - Steroid sensitive nephrotic syndrome - History of genetic defects known to directly cause nephrotic syndrome (i.e., NPHS2 [podocin], NPHS1 [nephrin], PLCE1, WT1, or other known genetic cause) - Any known inflammatory condition - History of cardiac disease (arrhythmias, structural/functional abnormalities) - Implantable electronic devices (pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators) - Chronic rash or skin breakdown of the left ear at the cymba concha - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
trascutaneous auricular vagus nerve stimulation
The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
Sham device
The device will appear to function but no electrical stimulation will be delivered.

Locations

Country Name City State
United States Cohen Children's Medical Center New Hyde Park New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Northwell Health National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success of Pilot Trial Unsuccessful: main study not practicable
None of the primary feasibility and tolerability benchmarks are met, or
One or more of the primary benchmarks are not met and there is low likelihood of reaching benchmarks even with protocol modifications or
Serious adverse events related to the treatment.
Probable Success: main study practicable with modifications to protocol. One or more of the primary benchmarks are not met, but there is a high likelihood that the benchmark can be met with protocol modifications.
Successful: main study practicable without modifications. All of the primary benchmarks are met.
Baseline to 26 weeks
Secondary Effect size for change in Change in quality of life (PedsQL) To calculate effect sizes for continuous main trial efficacy outcomes using a t test, Cohen's d test will be used. Baseline to 26 weeks
Secondary Effect size for change in urine protein:creatinine To calculate effect sizes for continuous main trial efficacy outcomes using a t test, Cohen's d test will be used. Baseline to 26 weeks
Secondary Effect size for change in lipid profile To calculate effect sizes for continuous main trial efficacy outcomes using a t test, Cohen's d test will be used. Baseline to 26 weeks
Secondary Effect size for change in proportion with at least a 30 percent reduction in UPC To estimate effect sizes for dichotomous main trial efficacy outcomes using Fisher's exact test, odds ratios will be calculated outcomes using a t test, Cohen's d test will be used. Baseline to 26 weeks
Secondary Recruitment rate Feasibility- % Baseline to 26 weeks
Secondary Rate of completion of study Feasibility- % Baseline to 26 weeks
Secondary Successful double-blinding Feasibility- % Baseline to 26 weeks
Secondary Treatment adherence from home logs Feasibility- % Baseline to 26 weeks
Secondary Adverse events Tolerability- % Baseline to 26 weeks
Secondary Incidence of withdrawal due to adverse events Tolerability- % Baseline to 26 weeks
Secondary Proof of Concept Decision Criteria A decision of whether to move forward with a larger trial will be made based on pre-determined proof of concept decision criteria. Once data from the two pilot trials are observed and collected, 1,000 bootstrap resamples with replacement will be carried out to construct the empirical 95% confidence interval (CI) for the relative risk. Baseline to 26 weeks
Secondary Cytokines TNF, IL-6 Baseline to 26 weeks
Secondary Anti-nephrin antibodies Baseline to 26 weeks
Secondary Whole blood monocyte stimulation test Change in monocyte cytokines at baseline and 2 hours post taVNS 0 hours, 2 hours
See also
  Status Clinical Trial Phase
Completed NCT02585804 - Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Phase 4
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Not yet recruiting NCT00956059 - Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Completed NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT01113385 - Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome N/A
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT03703908 - A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome Phase 2
Completed NCT03649152 - Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT00255398 - Kidney Disease Biomarkers
Terminated NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Recruiting NCT02235857 - Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children N/A
Recruiting NCT05942625 - A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects Phase 1
Recruiting NCT02382874 - Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Phase 1
Completed NCT00464321 - Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS Phase 1
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis